CY1121924T1 - Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα - Google Patents
Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελταInfo
- Publication number
- CY1121924T1 CY1121924T1 CY20191100571T CY191100571T CY1121924T1 CY 1121924 T1 CY1121924 T1 CY 1121924T1 CY 20191100571 T CY20191100571 T CY 20191100571T CY 191100571 T CY191100571 T CY 191100571T CY 1121924 T1 CY1121924 T1 CY 1121924T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- virus infection
- hepatitis virus
- delta hepatitis
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987315P | 2014-05-01 | 2014-05-01 | |
| US201462044766P | 2014-09-02 | 2014-09-02 | |
| US201462073413P | 2014-10-31 | 2014-10-31 | |
| US201562151349P | 2015-04-22 | 2015-04-22 | |
| PCT/US2015/028933 WO2015168648A1 (en) | 2014-05-01 | 2015-05-01 | Treatment of hepatitis delta virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121924T1 true CY1121924T1 (el) | 2020-10-14 |
Family
ID=54359409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100571T CY1121924T1 (el) | 2014-05-01 | 2019-05-29 | Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3137078B1 (enExample) |
| JP (1) | JP6490800B2 (enExample) |
| KR (3) | KR102686313B1 (enExample) |
| CN (2) | CN111265525A (enExample) |
| CY (1) | CY1121924T1 (enExample) |
| DK (1) | DK3137078T3 (enExample) |
| ES (1) | ES2728405T3 (enExample) |
| HU (1) | HUE044606T2 (enExample) |
| LT (1) | LT3137078T (enExample) |
| PL (1) | PL3137078T3 (enExample) |
| PT (1) | PT3137078T (enExample) |
| SI (1) | SI3137078T1 (enExample) |
| WO (1) | WO2015168648A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| CN107530338B (zh) | 2015-04-21 | 2020-12-01 | 艾格尔峰生物制药有限公司 | 包含洛那法尼和利托那韦的药物组合物 |
| EP3858352A1 (en) * | 2015-11-04 | 2021-08-04 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| KR20180110127A (ko) * | 2016-02-19 | 2018-10-08 | 아이거 바이오파마슈티컬스 인코포레이티드 | 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료 |
| JP2020510480A (ja) * | 2017-03-01 | 2020-04-09 | ナショナル ユニバーシティ オブ シンガポール | マイクロニードルデバイス |
| WO2024223797A1 (en) * | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| CA2424222A1 (en) * | 2000-10-02 | 2002-04-11 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| EP1365763B1 (en) * | 2001-02-15 | 2008-11-26 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
| WO2005117864A1 (en) * | 2004-05-28 | 2005-12-15 | Astrazeneca Ab | Combination product comprising anastrozole and a dual prenyl transferase inhibitor |
| US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| EP1998759A2 (en) * | 2006-03-23 | 2008-12-10 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| WO2008137692A1 (en) * | 2007-05-03 | 2008-11-13 | Link Medicine Corporation | Treatment of synucleinopathies |
| US20090087483A1 (en) | 2007-09-27 | 2009-04-02 | Sison Raymundo A | Oral dosage combination pharmaceutical packaging |
| US20110313009A1 (en) | 2008-07-17 | 2011-12-22 | Horizon Pharma Usa, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
| EP2421527B1 (en) * | 2009-04-25 | 2018-06-13 | F.Hoffmann-La Roche Ag | Methods for improving pharmacokinetics |
| WO2011088126A2 (en) * | 2010-01-13 | 2011-07-21 | Eiger Biopharmaceuticals, Inc. | Treatment of viral infection with prenyltransferase inhibitors |
-
2015
- 2015-05-01 CN CN202010069655.XA patent/CN111265525A/zh active Pending
- 2015-05-01 CN CN201580023585.1A patent/CN106535895B/zh active Active
- 2015-05-01 EP EP15785846.5A patent/EP3137078B1/en active Active
- 2015-05-01 DK DK15785846.5T patent/DK3137078T3/da active
- 2015-05-01 SI SI201530762T patent/SI3137078T1/sl unknown
- 2015-05-01 KR KR1020167033817A patent/KR102686313B1/ko active Active
- 2015-05-01 JP JP2017510458A patent/JP6490800B2/ja active Active
- 2015-05-01 LT LTEP15785846.5T patent/LT3137078T/lt unknown
- 2015-05-01 KR KR1020247023478A patent/KR20240112990A/ko active Pending
- 2015-05-01 ES ES15785846T patent/ES2728405T3/es active Active
- 2015-05-01 HU HUE15785846 patent/HUE044606T2/hu unknown
- 2015-05-01 WO PCT/US2015/028933 patent/WO2015168648A1/en not_active Ceased
- 2015-05-01 KR KR1020237014993A patent/KR20230062688A/ko not_active Ceased
- 2015-05-01 EP EP19162000.4A patent/EP3620163A1/en active Pending
- 2015-05-01 PL PL15785846T patent/PL3137078T3/pl unknown
- 2015-05-01 PT PT15785846T patent/PT3137078T/pt unknown
-
2019
- 2019-05-29 CY CY20191100571T patent/CY1121924T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6490800B2 (ja) | 2019-03-27 |
| HUE044606T2 (hu) | 2019-11-28 |
| CN111265525A (zh) | 2020-06-12 |
| CN106535895A (zh) | 2017-03-22 |
| KR20170005827A (ko) | 2017-01-16 |
| EP3620163A1 (en) | 2020-03-11 |
| ES2728405T3 (es) | 2019-10-24 |
| SI3137078T1 (sl) | 2019-08-30 |
| KR20230062688A (ko) | 2023-05-09 |
| PL3137078T3 (pl) | 2019-08-30 |
| KR20240112990A (ko) | 2024-07-19 |
| LT3137078T (lt) | 2019-06-25 |
| PT3137078T (pt) | 2019-06-11 |
| EP3137078B1 (en) | 2019-03-20 |
| JP2017514911A (ja) | 2017-06-08 |
| EP3137078A1 (en) | 2017-03-08 |
| WO2015168648A1 (en) | 2015-11-05 |
| CN106535895B (zh) | 2020-02-28 |
| EP3137078A4 (en) | 2017-11-15 |
| DK3137078T3 (da) | 2019-06-11 |
| KR102686313B1 (ko) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121924T1 (el) | Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα | |
| CY1125214T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| CY1123962T1 (el) | Μεθοδοι και φαρμακευτικες συνθεσεις για την αγωγη της λοιμωξης απο τον ιο της ηπατιτιδας β | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| EP3893940A4 (en) | Combination therapy for treating muscular dystrophy | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| MX2018005230A (es) | Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. | |
| UA117518C2 (uk) | 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b | |
| BR112017012859A2 (pt) | fosforamidatos para o tratamento do vírus da hepatite b | |
| JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
| EA201691440A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
| EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
| EA201690979A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
| CY1120607T1 (el) | Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης | |
| CY1124507T1 (el) | Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| CY1124220T1 (el) | Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα με ιντερφερονη λαμδα | |
| MX387283B (es) | Tratamiento del cancer con tg02. | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| MX2018004132A (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
| EA201790700A1 (ru) | Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге | |
| MX388408B (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv | |
| CY1123532T1 (el) | Αναστολεις του gingipain λυσινης | |
| MX2018010709A (es) | Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. | |
| CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου |